false 0001472012 Immunome Inc. 0001472012 2024-06-12 2024-06-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 12, 2024

 

 

Immunome, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware   001-39580   77-0694340
(State or other jurisdiction
of incorporation)
  (Commission
File Number) 
  (IRS Employer
Identification No.)

 

18702 N. Creek Parkway, Suite 100
Bothell
, Washington
  98011
(Address of principal executive offices)     (Zip Code)

 

Registrant’s telephone number, including area code: (610) 321-3700

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)
  Name of each exchange
on which registered
Common Stock, $0.0001 par value per share   IMNM   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

Item 5.07Submission of Matters to a Vote of Security Holders

 

Immunome, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders on June 12, 2024 (the “Annual Meeting”). As of April 25, 2024, the record date for the Annual Meeting, 59,943,368 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.

 

Proposal 1: Election of Directors

 

The Company’s stockholders elected the two persons below as Class I Directors, each to serve until the Company’s 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows:

 

   Votes For  Votes Withheld  Broker Non-Votes
Clay B. Siegall, Ph.D.  43,295,914  80,139  6,682,195
Carol A. Schafer  33,452,580  9,923,473  6,682,195

 

Proposal 2: Ratification of Selection of Independent Registered Public Accounting Firm

 

The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The final voting results are as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
50,008,641   29,664   19,943  

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  IMMUNOME, INC.
   
Date: June 13, 2024 By: /s/ Max Rosett
  Name: Max Rosett
  Title: Chief Financial Officer

 

 

 

v3.24.1.1.u2
Cover
Jun. 12, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 12, 2024
Entity File Number 001-39580
Entity Registrant Name Immunome Inc.
Entity Central Index Key 0001472012
Entity Tax Identification Number 77-0694340
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 18702 N. Creek Parkway, Suite 100
Entity Address, City or Town Bothell
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98011
City Area Code 610
Local Phone Number 321-3700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol IMNM
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false

Immunome (NASDAQ:IMNM)
過去 株価チャート
から 5 2024 まで 6 2024 Immunomeのチャートをもっと見るにはこちらをクリック
Immunome (NASDAQ:IMNM)
過去 株価チャート
から 6 2023 まで 6 2024 Immunomeのチャートをもっと見るにはこちらをクリック